Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)
Biomarker and diagnostic research for acute leukemia of ambiguous lineage has been reported in the published literature.
61 clinical trials registered, 21 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 1 PHASE4, 7 PHASE3, 23 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06317662](https://clinicaltrials.gov/study/NCT06317662) |
Data assembled from 4 of 12 sources · Last updated Nov 18, 2026, 6:00 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute leukemia of ambiguous lineage
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia |
PHASE2 |
National Cancer Institute (NCI) |
RECRUITING |
[NCT05322850](https://clinicaltrials.gov/study/NCT05322850) | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | PHASE1 | University of Florida | RECRUITING |
[NCT07356154](https://clinicaltrials.gov/study/NCT07356154) | A Study of Revumenib and Mezigdomide in People With Leukemia | PHASE1 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT06177067](https://clinicaltrials.gov/study/NCT06177067) | Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | PHASE1 | St. Jude Children's Research Hospital | RECRUITING |
[NCT03959085](https://clinicaltrials.gov/study/NCT03959085) | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | PHASE3 | Children's Oncology Group | RECRUITING |
29 publications have been identified in PubMed for acute leukemia of ambiguous lineage. Research spans Case Report / Case Series (31%), Review / Meta-Analysis (24%), and Gene Therapy / Novel Therapeutics (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 31% |
Research summaries | 7 | 24% |
New treatment approaches | 4 | 14% |
Testing and diagnosis research | 3 | 10% |
Clinical study results | 3 | 10% |
Laboratory research | 3 | 10% |
Wang SA (2026). [PMID: 40905082](https://pubmed.ncbi.nlm.nih.gov/40905082/). *Haematologica*. [Gene Therapy / Novel Therapeutics]
Sherban A (2026). [PMID: 41063702](https://pubmed.ncbi.nlm.nih.gov/41063702/). *Haematologica*. [Review / Meta-Analysis]
Li Y (2026). [PMID: 41540127](https://pubmed.ncbi.nlm.nih.gov/41540127/). *Annals of hematology*. [Clinical Trial Publication]
Wang WJ (2026). [PMID: 41195731](https://pubmed.ncbi.nlm.nih.gov/41195731/). *American journal of hematology*. [Gene Therapy / Novel Therapeutics]
Stokol T (2026). [PMID: 41546140](https://pubmed.ncbi.nlm.nih.gov/41546140/). *Veterinary clinical pathology*. [Diagnostic / Biomarker]
Biswas D (2026). [PMID: 41717956](https://pubmed.ncbi.nlm.nih.gov/41717956/). *Indian journal of pathology & microbiology*. [Diagnostic / Biomarker]
Saft L (2026). [PMID: 41948832](https://pubmed.ncbi.nlm.nih.gov/41948832/). *American journal of clinical pathology*. [Review / Meta-Analysis]
Zhang A (2026). [PMID: 41988760](https://pubmed.ncbi.nlm.nih.gov/41988760/). *Haematologica*. [Basic Science / Preclinical]
Shibeeb S (2026). [PMID: 41975767](https://pubmed.ncbi.nlm.nih.gov/41975767/). *Diagnostics (Basel)*. [Review / Meta-Analysis]
Fei F (2026). [PMID: 42248548](https://pubmed.ncbi.nlm.nih.gov/42248548/). *J Mol Diagn*. [Basic Science / Preclinical]